Recently I had the privilege of meeting Dr. T Vollmer, a co-author of the article "B-Cell Depletion with Rituximab in RRMS" in the New England Journal of Medicine. Meeting Dr. Vollmer was the result of soliciting for participation in the Alemtuzumab (Campath) vs Rebif trial. Although we bo...